Thursday, November 20, 2025 7:04:14 AM
$3.43 quick cash out doesn't stay up long usually
Recent PBM News
- Psyence BioMed Initiates Patient Dosing in Phase IIb Trial Evaluating NPX-5 for Adjustment Disorder • GlobeNewswire Inc. • 04/23/2026 11:00:00 AM
- Psyence BioMed Positioned as World's only Licensed Pharmaceutical Grade Ibogaine Supplier at Source • GlobeNewswire Inc. • 04/20/2026 11:42:20 AM
- Psyence BioMed Welcomes U.S. Executive Action to Advance Research into Ibogaine • GlobeNewswire Inc. • 04/17/2026 01:15:00 PM
- Psyence BioMed Expands Australian Clinical Site Network to Five Sites, Advancing NPX-5–Supported Clinical Activities • GlobeNewswire Inc. • 04/08/2026 01:15:00 PM
- Psyence BioMed Advances Vertically Integrated Pharmaceutical Platform Following PsyLabs Export Milestone • GlobeNewswire Inc. • 03/11/2026 01:15:00 PM
- Psyence BioMed Announces Export of GMP-Manufactured Natural Psilocybin (NPX-5) to Australia for Ongoing Phase IIb Clinical Trial • GlobeNewswire Inc. • 03/03/2026 02:15:00 PM
- Psyence Biomedical Shares Rise Following Equity Investment Agreement • IH Market News • 02/23/2026 04:16:10 PM
- Psyence BioMed Announces Exercise of Put Option by PsyLabs and Strategic Equity Investment • GlobeNewswire Inc. • 02/20/2026 10:20:00 PM
- Psyence BioMed Announces Results of Annual and Special Meeting of Shareholders • GlobeNewswire Inc. • 02/17/2026 02:15:00 PM
- Psyence BioMed Approves Put Option Agreement with PsyLabs to Secure Strategic Supply and Strengthen Commercialization Pathway • GlobeNewswire Inc. • 02/13/2026 11:30:00 PM
- Psyence BioMed Announces Settlement of Shareholder Litigation • GlobeNewswire Inc. • 02/11/2026 02:15:00 PM
- Psyence BioMed Announces Effective Date for 1-for-6.25 Reverse Stock Split • GlobeNewswire Inc. • 01/28/2026 11:30:00 PM
- Psyence BioMed Announces Adjournment of Annual and Special Shareholder Meeting on January 22, 2026 • GlobeNewswire Inc. • 01/22/2026 06:42:41 PM
- Psyence BioMed Announces Postponement of Previously Announced Reverse Stock Split Effective Date • GlobeNewswire Inc. • 01/20/2026 12:19:41 PM
- Psyence BioMed Announces Effective Date for 1-for-6.25 Reverse Stock Split • GlobeNewswire Inc. • 01/15/2026 12:00:00 AM
- Psyence BioMed Approves 2026 Financial Strategy, Board Authorizes Share Buyback on Value Opportunity • GlobeNewswire Inc. • 01/12/2026 01:30:00 PM
- Psyence BioMed Achieves Milestone in Natural Ibogaine HCl Production and Strengthens Balance Sheet With No Debt and $12m Cash • GlobeNewswire Inc. • 01/05/2026 02:15:00 PM
- Psyence BioMed Announces Approval for Use of PsyLabs’ Psilocybin Product in Phase IIb Clinical Trial • GlobeNewswire Inc. • 12/19/2025 12:00:00 PM
- Psyence BioMed CEO Letter Highlights Clinical Progress, Ethical Sourcing of Ibogaine, Strong Cash Position and Expanding Leadership in Longevity Science • GlobeNewswire Inc. • 12/09/2025 12:00:00 PM
- Psyence BioMed Announces Groundbreaking Psilocybin Longevity Research Program • GlobeNewswire Inc. • 11/25/2025 12:00:00 PM
- Psyence BioMed Reaches Major Breakthrough in Pharmaceutical-Grade Ibogaine Supply for Worldwide Clinical and Therapeutic Markets • GlobeNewswire Inc. • 11/20/2025 12:00:00 PM
- Psyence BioMed Establishes Ibogaine Operations in Africa Through Strategic Investment in PsyLabs • GlobeNewswire Inc. • 11/12/2025 12:00:00 PM
- Psyence BioMed Doses Multiple Patients and Expands Clinical Sites in Phase IIb Study for Adjustment Disorder in Palliative Care • GlobeNewswire Inc. • 11/06/2025 12:00:00 PM
- Psyence BioMed Strengthens Strategic Partnership with PsyLabs Through USD $3,500,000 Follow-On Investment • GlobeNewswire Inc. • 11/03/2025 12:00:00 PM
- Psyence BioMed to Present at the H.C. Wainwright 27th Annual Global Investment Conference September 8-10, 2025 • GlobeNewswire Inc. • 08/28/2025 12:00:00 PM
